Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

GeneDx Holdings (WGS) EBIAT (2020 - 2026)

GeneDx Holdings has reported EBIAT over the past 7 years, most recently at -$63.3 million for Q1 2026.

  • Quarterly EBIAT fell 869.77% to -$63.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$77.8 million through Mar 2026, down 101.7% year-over-year, with the annual reading at -$21.0 million for FY2025, 59.8% up from the prior year.
  • EBIAT was -$63.3 million for Q1 2026 at GeneDx Holdings, down from -$17.7 million in the prior quarter.
  • Over five years, EBIAT peaked at $10.8 million in Q2 2025 and troughed at -$308.8 million in Q4 2022.
  • The 5-year median for EBIAT is -$29.2 million (2024), against an average of -$50.7 million.
  • Year-over-year, EBIAT skyrocketed 137.05% in 2025 and then plummeted 869.77% in 2026.
  • A 5-year view of EBIAT shows it stood at -$308.8 million in 2022, then skyrocketed by 91.65% to -$25.8 million in 2023, then surged by 121.1% to $5.4 million in 2024, then plummeted by 424.86% to -$17.7 million in 2025, then plummeted by 258.41% to -$63.3 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's EBIAT are -$63.3 million (Q1 2026), -$17.7 million (Q4 2025), and -$7.6 million (Q3 2025).